Respiratory Today—May 29, 2026

This week’s Respiratory research update highlights regulatory progress, clinical development milestones, diagnostic advances, and market-access activity across fibrosis, allergy, bronchiectasis, and PH-ILD.

In Today’s Newsletter

Dive deeper

💨 RESP-X Phase IIa bronchiectasis data [1] [UK • 21 May 2026]

https://www.infextx.com/infex-therapeutics-announces-positive-phase-iia-results-for-resp-x-in-non-cystic-fibrosis-bronchiectasis-patients-colonised-with-pseudomonas-aeruginosa/
Context: Infex Therapeutics evaluated RESP-X (INFEX702), an anti-virulence monoclonal antibody, in Phase IIa NCFB patients colonised with Pseudomonas aeruginosa.
Key point: The study met primary and secondary objectives, showing safety, tolerability, favorable PK, no immunogenicity, and early efficacy signals.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Sunshine Biopharma generic amoxicillin approval [2] [Canada • 21 May 2026]

https://sunshinebiopharma.com/wp-content/uploads/2026/05/20260521_SBFM_Press-Release_Approval-for-Amoxicillin.pdf
Context: Sunshine Biopharma received Canadian approval for generic amoxicillin in multiple dosage forms and strengths.
Key point: The company expects the product to ship to pharmacies in Aug 2026.
Implication: Introduces competition that may affect pricing and formulary access.

🌿 Actair IND clearance in China [3] [China • 22 May 2026]

https://www.prnewswire.com/apac/news-releases/nuance-pharma-announces-ind-clearance-for-actair-pivotal-clinical-trial-in-china-302779685.html
Context: Nuance Pharma and Stallergenes Greer are advancing Actair for house dust mite-induced allergic rhinitis in China.
Key point: NMPA cleared the IND for a Phase III randomized, double-blind, placebo-controlled 12-month trial.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 JASCAYD CHMP positive opinion for IPF and PPF [4] [EU • 22 May 2026]

https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/chmp-issues-positive-opinion-jascayd-ipf-and-ppf-eu
Context: Boehringer Ingelheim’s JASCAYD (nerandomilast) is an oral preferential PDE4B inhibitor for IPF and PPF.
Key point: CHMP recommended EU marketing authorization, based on Phase III FIBRONEER data showing slowed FVC decline versus placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 ViraxImmune early PAIS pilot data [5] [UK • 26 May 2026]

https://www.prnewswire.com/news-releases/virax-biolabs-reports-positive-early-clinical-data-for-viraximmune-in-long-covid-and-related-post-acute-infection-syndromes-302778628.html
Context: Virax Biolabs is developing ViraxImmune, a blood-based immune-profiling test for Long COVID, ME/CFS, and related PAIS.
Key point: Pilot data showed measurable separation between PAIS patients and healthy controls, with larger validation planned.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧬 CS014 PK-bridging study starts in Sweden [6] [Sweden • 26 May 2026]

https://www.cerenoscientific.com/en/newsroom/press-releases?slug=cereno-scientific-confirms-first-volunteer-dosed-in-cs014-pk-bridging-study-supporting-phase-ii-development-in-ph-ild
Context: Cereno Scientific dosed the first volunteer in a Phase I PK-bridging study of CS014, a deuterated HDAC inhibitor.
Key point: The FDA-aligned study compares CS014 with valproic acid in 14 healthy adults and supports Phase IIb planning in PH-ILD.
Implication: Signals pipeline investment and modality expansion.

🛡️ PAPZIMEOS orphan drug exclusivity in the US [7] [US • 27 May 2026]

https://investors.precigen.com/news-releases/news-release-details/precigen-receives-orphan-drug-exclusivity-papzimeos-zopapogene
Context: Precigen’s PAPZIMEOS (zopapogene imadenovec-drba) is FDA-approved for adults with recurrent respiratory papillomatosis.
Key point: FDA granted orphan drug exclusivity, giving US market exclusivity through 14 Aug 2032.
Implication: Introduces competition that may affect pricing and formulary access.

Why it matters

Respiratory disease pipelines remain active across fibrosis, bronchiectasis, allergy, PH-ILD, and post-acute infection syndromes.
Regulatory momentum is prominent, with CHMP, NMPA, FDA, and Canadian approvals or clearances in the same news window.
Multiple stories point to market-access inflection points, including EU authorization review, Canadian generic launch planning, and US exclusivity.
Early-stage diagnostic and PK-bridging data remain hypothesis-generating until larger validation or efficacy datasets read out.

📚 See the full Respiratory archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Respiratory news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is RESP-X from Infex Therapeutics?

RESP-X (INFEX702) is a first-in-class anti-virulence monoclonal antibody targeting Pseudomonas aeruginosa in NCFB. Phase IIa data showed safety, tolerability, favorable PK, and early efficacy signals. [1]

What changed for Sunshine Biopharma’s amoxicillin in Canada?

Sunshine Biopharma received Canadian regulatory approval for generic amoxicillin. The company expects shipment to pharmacies in Aug 2026. [2]

What is Actair, and what did Nuance Pharma receive in China?

Actair is a house dust mite allergy immunotherapy tablet. Nuance Pharma received NMPA IND clearance to start a pivotal Phase III trial in China. [3]

What does the CHMP opinion mean for JASCAYD?

CHMP issued a positive opinion for JASCAYD (nerandomilast) in adults with IPF and PPF. European Commission approval would be the next EU step. [4]

Is ViraxImmune approved for diagnostic use?

No. ViraxImmune is in development and is not approved for diagnostic use in any jurisdiction. The reported data are early pilot findings. [5]

What did FDA exclusivity add for PAPZIMEOS?

FDA granted orphan drug exclusivity for PAPZIMEOS in adult recurrent respiratory papillomatosis, effective through 14 Aug 2032. [7]

Entities / Keywords

Infex Therapeutics, RESP-X, INFEX702, Pseudomonas aeruginosa, NCFB, bronchiectasis, anti-virulence monoclonal antibody
Sunshine Biopharma, generic amoxicillin, Canada, antibiotics
Nuance Pharma, Stallergenes Greer, Actair, Orylmyte, Aitmyte, house dust mite allergy, allergic rhinitis, NMPA
Boehringer Ingelheim, JASCAYD, nerandomilast, IPF, PPF, PDE4B inhibitor, FIBRONEER
Virax Biolabs, ViraxImmune, Long COVID, ME/CFS, PAIS, immune profiling
Cereno Scientific, CS014, HDAC inhibitor, PK bridging, PH-ILD
Precigen, PAPZIMEOS, zopapogene imadenovec-drba, recurrent respiratory papillomatosis, RRP, orphan drug exclusivity